141 related articles for article (PubMed ID: 26973907)
21. Patient-perceived barriers and facilitators to the implementation of a medication review in primary care: a qualitative thematic analysis.
Uhl MC; Muth C; Gerlach FM; Schoch GG; Müller BS
BMC Fam Pract; 2018 Jan; 19(1):3. PubMed ID: 29304725
[TBL] [Abstract][Full Text] [Related]
22. Perceptions of barriers and facilitators of cancer early detection among low-income minority women in community health centers.
Ogedegbe G; Cassells AN; Robinson CM; DuHamel K; Tobin JN; Sox CH; Dietrich AJ
J Natl Med Assoc; 2005 Feb; 97(2):162-70. PubMed ID: 15712779
[TBL] [Abstract][Full Text] [Related]
23. Barriers and facilitators to uptake of cervical cancer screening among women in Uganda: a systematic review.
Black E; Hyslop F; Richmond R
BMC Womens Health; 2019 Aug; 19(1):108. PubMed ID: 31399092
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with perceived risk in automotive employees at increased risk of colorectal cancer.
Vernon SW; Myers RE; Tilley BC; Li S
Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):35-43. PubMed ID: 11205487
[TBL] [Abstract][Full Text] [Related]
25. Barriers and Facilitators to Colorectal Cancer Screening Within a Hispanic Population.
Byrd TL; Calderón-Mora J; Salaiz R; Shokar NK
Hisp Health Care Int; 2019 Mar; 17(1):23-29. PubMed ID: 30574791
[TBL] [Abstract][Full Text] [Related]
26. Cancer screening barriers and facilitators for under and never screened populations: A mixed methods study.
Gesink D; Filsinger B; Mihic A; Norwood TA; Sarai Racey C; Perez D; Antal J; Ritvo P; Vernich L
Cancer Epidemiol; 2016 Dec; 45():126-134. PubMed ID: 27810484
[TBL] [Abstract][Full Text] [Related]
27. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
Saito H; Soma Y; Nakajima M; Koeda J; Kawaguchi H; Kakizaki R; Chiba R; Aisawa T; Munakata A
Oncol Rep; 2000; 7(4):815-9. PubMed ID: 10854550
[TBL] [Abstract][Full Text] [Related]
28. Perceived Barriers and Facilitators for Return to Work Among Colorectal Cancer Survivors: Malaysian Healthcare Professionals Experience- A Qualitative Inquiry.
Chow SL; Loh SY; Su TT
J UOEH; 2015 Jun; 37(2):127-38. PubMed ID: 26073502
[TBL] [Abstract][Full Text] [Related]
29. Barriers to and facilitators of colorectal cancer screening in different population subgroups in Adelaide, South Australia.
Javanparast S; Ward PR; Carter SM; Wilson CJ
Med J Aust; 2012 May; 196(8):521-3. PubMed ID: 22571311
[TBL] [Abstract][Full Text] [Related]
30. Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer.
Castiglione G; Zappa M; Grazzini G; Mazzotta A; Biagini M; Salvadori P; Ciatto S
Br J Cancer; 1996 Jul; 74(1):141-4. PubMed ID: 8679448
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer screening beliefs. Focus groups with first-degree relatives.
Rawl SM; Menon U; Champion VL; Foster JL; Skinner CS
Cancer Pract; 2000; 8(1):32-7. PubMed ID: 10732537
[TBL] [Abstract][Full Text] [Related]
32. A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening.
Raginel T; Puvinel J; Ferrand O; Bouvier V; Levillain R; Ruiz A; Lantieri O; Launoy G; Guittet L
Gastroenterology; 2013 May; 144(5):918-25. PubMed ID: 23376426
[TBL] [Abstract][Full Text] [Related]
33. Knowledge, facilitators and perceived barriers for early detection of breast cancer among elderly Turkish women.
Kissal A; Beşer A
Asian Pac J Cancer Prev; 2011; 12(4):975-84. PubMed ID: 21790237
[TBL] [Abstract][Full Text] [Related]
34. Crafting Appealing Text Messages to Encourage Colorectal Cancer Screening Test Completion: A Qualitative Study.
Weaver KE; Ellis SD; Denizard-Thompson N; Kronner D; Miller DP
JMIR Mhealth Uhealth; 2015 Nov; 3(4):e100. PubMed ID: 26537553
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing participation in colorectal cancer screening-a qualitative study in an ethnic and socio-economically diverse inner city population.
Dharni N; Armstrong D; Chung-Faye G; Wright AJ
Health Expect; 2017 Aug; 20(4):608-617. PubMed ID: 27550367
[TBL] [Abstract][Full Text] [Related]
36. Influence of the 'directions for use' on positivity rates of the Hemoccult II test.
Faure H; Exbrayat C; Garnier A; Dumas P; Winckel P; Bolla M
Eur J Gastroenterol Hepatol; 1998 Dec; 10(12):1021-4. PubMed ID: 9895048
[TBL] [Abstract][Full Text] [Related]
37. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
38. Obstacles to colorectal screening in general practice: a qualitative study of GPs and patients.
Aubin-Auger I; Mercier A; Lebeau JP; Baumann L; Peremans L; Van Royen P
Fam Pract; 2011 Dec; 28(6):670-6. PubMed ID: 21551256
[TBL] [Abstract][Full Text] [Related]
39. [Preliminary validation of the French translation of anxiety sensibility index-revised (ASI-R)].
Bouvard M; Ayxères-Vighetto A; Dupont H; Aupetit J; Portalier S; Arrindell W
Encephale; 2003; 29(2):157-64. PubMed ID: 14567167
[TBL] [Abstract][Full Text] [Related]
40. Interval cancers in screening with fecal occult blood test for colorectal cancer.
Jensen BM; Kronborg O; Fenger C
Scand J Gastroenterol; 1992 Sep; 27(9):779-82. PubMed ID: 1411286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
